ストックスクリーナーアプリを入手
10.46
4.08%
0.41
アフターアワーズ：
10.41
-0.05
-0.48%
前日終値:
$10.05
開ける：
$10
24時間の取引高:
2.24M
Relative Volume:
0.68
時価総額：
$1.67B
収益：
$68.56M
当期純損益:
$-437.99M
株価収益率:
-3.306
EPS:
-3.1639
ネットキャッシュフロー:
$-396.61M
1週間 パフォーマンス:
+9.87%
1か月 パフォーマンス:
+12.96%
6か月 パフォーマンス:
+72.32%
1年 パフォーマンス:
+86.12%
1日の値動き範囲:
$9.95
$10.47
1週間の範囲:
$9.06
$10.47
52週間の値動き範囲:
$4.155
$10.94
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.46 | 1.61B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 開始されました | Evercore ISI | Outperform |
| 2025-08-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Vir Biotechnology Rings the Closing Bell - Nasdaq
A Look At Vir Biotechnology (VIR) Valuation After New VIR-5500 Prostate Cancer Trial Milestone - Yahoo Finance
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer - BioSpace
Vir Biotechnology Q1 2025 Earnings Preview - MSN
Vir Biotechnology doses first patient in VIR-5500 expansion trial By Investing.com - Investing.com Australia
Vir Biotechnology (VIR) Advances Phase 1 Trial with First Patien - GuruFocus
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-ta - PharmiWeb.com
Vir Biotechnology doses first patient in VIR-5500 expansion trial - Investing.com
Vir Biotech CEO Stock Sale: $664K Transaction in April 2026News and Statistics - IndexBox
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 - The Motley Fool
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 - The Motley Fool
VIR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vir Biotechnology Announces Upcoming Chief Medical Officer Transition - TipRanks
Vir Biotechnology (NASDAQ: VIR) Chief Medical Officer to step down April 24 - Stock Titan
Quarterly Risk: Can Vir Biotechnology Inc be recession proof2026 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Vir Biotechnology (VIR) Leading with Its BiTEs Therapy - Insider Monkey
Vir Biotechnology’s CMO Change Already Reflected in Valuation—Attention Shifts to Execution Risks for VIR-5500 - Bitget
Aberdeen Group plc Sells 135,688 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vir Biotechnology CEO de Backer sells $664k in stock By Investing.com - Investing.com Canada
Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 72,559 Shares - MarketBeat
Vir Biotechnology CEO de Backer sells $664k in stock - Investing.com
Vir Biotechnology (VIR) CEO auto-sells 72,559 shares to cover RSU tax - Stock Titan
VIR Biotechnology Inc (NASDAQ:VIR) Emerges as a High-Growth Momentum Pick - ChartMill
Exit Recap: What is the Moat Score of Vir Biotechnology Inc2026 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
VIR (NASDAQ: VIR) Form 144 shows 72,559-share sale after vesting - Stock Titan
Evercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation - MSN
VIR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Market Catalysts: Is Vir Biotechnology Inc a good stock for dollar cost averaging2026 Key Highlights & AI Powered Market Trend Analysis - baoquankhu1.vn
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Sells $199,540.00 in Stock - MarketBeat
Vir Biotechnology director Sato sells $199k in shares By Investing.com - za.investing.com
Vir Biotechnology director Sato sells $199k in shares - Investing.com
Vir Biotechnology (VIR) director sells 22,000 shares in open market - Stock Titan
Vir Biotechnology (VIR) price target increased by 26.10% to 20.74 - MSN
Energy Moves: Is Vir Biotechnology Inc stock a smart retirement pickPortfolio Update Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Bull Bear: Is Vir Biotechnology Inc stock heavily shortedNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
Investor Mood: How volatile is LGLWS stockWeekly Earnings Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Why did Vir Biotechnology stock surge 60% after-hours today? - MSN
Vanguard affiliates disaggregate holdings; VIR shows 0% ownership (VIR) - Stock Titan
These analysts boost their forecasts on Vir Biotechnology - msn.com
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):